MedTrace Logo

Exercise and Acarbose in Type 2 Diabetes

NCT01244971 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2010-11-22

No results posted yet for this study

Summary

The purpose of this study is to investigate the impact of exercise training, Acarbose, and the combination of exercise and Acarbose on glycemic control, body composition, insulin sensitivity and other cardiovascular risk markers in type 2 diabetes. Further, muscle biopsies will be obtain to study gene expression. Our hypothesis is that the combination therapy will be superior to monotherapy with exercise or Acarbose.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Acarbose

100mg, 3 times daily

BEHAVIORAL

Exercise

Moderate combined exercise, 50 minutes 3 times per week

OTHER

Exercise + Acarbose

See respective monotherapy description

Sponsors & Collaborators

Principal Investigators

  • Suad Efendic, Professor · Dpt of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2004-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01244971 on ClinicalTrials.gov